Skip to main content

Table 2 Persistence of pregabalin during follow-up

From: Persistence of pregabalin treatment in Taiwan: a nation-wide population-based study

  Duration of persistence (days)No. of patients with persistent pregabalin use
 No. of patientsMean (SD)Median (IQR)> = 90 days
~ < 180 days
> = 180 days
~ < 1 year
> = 1 year
~ < 2 years
> = 2 years
All cohort114,437149.5 (299.8)28 (14–118)33,570 (29.3)22,201 (19.4)13,885 (12.1)33,570 (29.3)
Specialties
Neurology53,910179.3 (330.4)41 (14–161)18,423 (34.2)12,623 (23.4)8165 (15.1)18,423 (34.2)
Anesthesiology5541189.8 (358)42 (14–166)1928 (34.8)1302 (23.5)829 (15)1928 (34.8)
Physiatry3151143.4 (301.1)28 (14–99)845 (26.8)566 (18)364 (11.6)845 (26.8)
Psychiatry430222.8 (383.9)56 (21–209)162 (37.7)117 (27.2)80 (18.6)162 (37.7)
Rheumatology9201206.6 (366.3)47 (21–191)3444 (37.4)2388 (26)1558 (16.9)3444 (37.4)
Others42,20493.3 (211.3)22 (7–69)8768 (20.8)5205 (12.3)2889 (6.8)8768 (20.8)
Indications
Herpes zoster34,91989.4 (224.1)21 (7–56)6405 (18.3)3700 (10.6)2134 (6.1)6405 (18.3)
Diabetic peripheral neuropathic pain13,369221.9 (330.1)71 (28–294)6044 (45.2)4381 (32.8)2894 (21.6)6044 (45.2)
Fibromyalgia21,051150.8 (302.8)28 (14–117)6179 (29.4)4026 (19.1)2470 (11.7)6179 (29.4)
Epilepsy3301515.5 (603.5)220 (35–814)2085 (63.2)1748 (53)1400 (42.4)2085 (63.2)
Other musculoskeletal diseases24,227138.3 (269.8)30 (14–113)7141 (29.5)4499 (18.6)2638 (10.9)7141 (29.5)
Others17,570158.6 (295.9)35 (14–141)5716 (32.5)3847 (21.9)2349 (13.4)5716 (32.5)
\